https://www.pharmaradar360.com/article/fda-approves-olumiant-for-adolescents-with-severe-alopecia-areata-e23cf93157e4c41bPharmaRadar360en2026-09-28T15:57:12.000ZFDA Approves Olumiant for Adolescents With Severe Alopecia Areatahttps://www.pharmaradar360.com/article/lawmakers-examine-challenges-facing-u-s-generic-drug-manufacturing-abe72f0b18e3bd4dPharmaRadar360en2026-09-28T15:55:46.000ZLawmakers Examine Challenges Facing U.S. Generic Drug Manufacturinghttps://www.pharmaradar360.com/article/hyperfine-names-roots-pharmaceutical-as-distributor-in-kuwait-and-uae-b78666bc753eab24PharmaRadar360en2026-09-28T15:42:08.000ZHyperfine names Roots Pharmaceutical as distributor in Kuwait and UAEhttps://www.pharmaradar360.com/article/india-secures-us-tariff-relief-for-specialty-pharmaceutical-products-93b38d894320a912PharmaRadar360en2026-09-28T15:31:49.000ZIndia Secures US Tariff Relief for Specialty Pharmaceutical Productshttps://www.pharmaradar360.com/article/china-s-lianya-pharmaceutical-sees-0-025-winning-rate-in-chinext-ipo-lottery-onl-9b9b0de2ab0b9bf8PharmaRadar360en2026-09-28T15:25:00.000ZChina's Lianya Pharmaceutical sees 0.025% winning rate in ChiNext IPO lottery; online subscription freezes over 12 trillion yuanhttps://www.pharmaradar360.com/article/three-women-say-they-almost-died-because-of-fda-approved-drug-06562f95ae61a366PharmaRadar360en2026-09-28T15:24:17.000ZThree women say they almost died because of FDA-approved drughttps://www.pharmaradar360.com/article/kras-g12d-inhibitor-s-2-13b-deal-tests-cross-border-tech-transfer-e8dbdf94ae0793b8PharmaRadar360en2026-09-28T15:13:07.000ZKRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transferhttps://www.pharmaradar360.com/article/lakewood-amedex-reports-positive-nu-3-mic-data-against-diabetic-foot-ulcer-clini-e7ce9a58b0bd3cb0PharmaRadar360en2026-09-28T14:57:47.000ZLakewood-Amedex Reports Positive Nu-3 MIC Data Against Diabetic Foot Ulcer Clinical Isolateshttps://www.pharmaradar360.com/article/rat-droppings-flies-roaches-tukaram-mundhe-s-team-shuts-mumbai-s-122-year-old-ky-207d7db76b2d4787PharmaRadar360en2026-09-28T14:49:19.000ZRat droppings, flies, roaches: Tukaram Mundhe's team shuts Mumbai's 122-year-old Kyani cafehttps://www.pharmaradar360.com/article/oncolytics-biotech-oncy-advances-clinical-trial-for-metastatic-colorectal-cancer-27aa93b793cf0ea2PharmaRadar360en2026-09-28T14:29:12.000ZOncolytics Biotech (ONCY) Advances Clinical Trial for Metastatic Colorectal Cancer Pelareorep Treatmenthttps://www.pharmaradar360.com/article/what-comes-next-for-west-pharmaceutical-services-nyse-wst-31a7da9591d54845PharmaRadar360en2026-09-28T14:27:00.000ZWhat Comes Next for West Pharmaceutical Services (NYSE:WST)?https://www.pharmaradar360.com/article/4d-molecular-therapeutics-initiates-patient-enrollment-in-phase-3-4sight-trial-f-f0f88a02cc99d741PharmaRadar360en2026-09-28T14:25:05.000Z4D Molecular Therapeutics Initiates Patient Enrollment in Phase 3 4SIGHT Trial for Diabetic Macular Edemahttps://www.pharmaradar360.com/article/michigan-attorney-tipped-family-about-pharmaceutical-companies-merger-sec-says-3ef1d39a2d396e48PharmaRadar360en2026-09-28T14:20:00.000ZMichigan attorney tipped family about pharmaceutical companies' merger, SEC sayshttps://www.pharmaradar360.com/article/leeds-review-sets-out-terms-of-reference-for-investigation-24ec70d5c42d1deaPharmaRadar360en2026-09-28T14:18:37.000ZLeeds review sets out terms of reference for investigationhttps://www.pharmaradar360.com/article/warum-der-blick-auf-medikamentenkosten-zu-kurz-greift-7a4051aab280f2c4PharmaRadar360en2026-09-28T14:14:48.000ZWarum der Blick auf Medikamentenkosten zu kurz greifthttps://www.pharmaradar360.com/article/this-biotech-company-added-nearly-3b-to-its-market-cap-here-s-why-kod-stock-is-r-0db7b4c3e818a3c8PharmaRadar360en2026-09-28T14:14:19.000ZThis Biotech Company Added Nearly $3B To Its Market Cap – Here’s Why KOD Stock Is Ripping Todayhttps://www.pharmaradar360.com/article/biotech-experts-want-u-s-policy-to-keep-pace-with-innovation-d317fcc114e40664PharmaRadar360en2026-09-28T14:06:58.000ZBiotech experts want U.S. policy to keep pace with innovationhttps://www.pharmaradar360.com/article/kodiak-sciences-says-eye-drug-on-par-with-regeneron-s-medicine-64599d833f273530PharmaRadar360en2026-09-28T14:05:22.000ZKodiak Sciences Says Eye Drug on Par with Regeneron's Medicinehttps://www.pharmaradar360.com/article/fda-upgrades-recall-of-blood-pressure-meds-distributed-nationwide-4d6b886a3b8a9b5aPharmaRadar360en2026-09-28T14:03:44.000ZFDA upgrades recall of blood pressure meds distributed nationwidehttps://www.pharmaradar360.com/article/novadip-biosciences-raises-10-4m-to-advance-clinical-trials-f7b0edcc936af5bcPharmaRadar360en2026-09-28T14:00:26.000ZNovadip Biosciences Raises €10.4M to Advance Clinical Trialshttps://www.pharmaradar360.com/article/oncolytics-biotech-inc-7d2b3c7e78dd55d6PharmaRadar360en2026-09-28T14:00:00.000ZOncolytics Biotech Inchttps://www.pharmaradar360.com/article/neonc-technologies-announces-fda-end-of-phase-1-meeting-for-neo212-ae07833ccffd4019PharmaRadar360en2026-09-28T13:59:10.000ZNeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212https://www.pharmaradar360.com/article/abbvie-wins-fda-nod-for-parkinson-s-pill-f4a6259ff8aa21b4PharmaRadar360en2026-09-28T13:44:59.000ZAbbVie wins FDA nod for Parkinson’s pillhttps://www.pharmaradar360.com/article/lib-therapeutics-and-sun-pharma-announce-global-licensing-commercialization-and-690ffccb3e554a00PharmaRadar360en2026-09-28T13:43:19.000ZLIB Therapeutics and Sun Pharma Announce Global Licensing, Commercialization and Manufacturing Agreement for Lerodalcibep, a Novel PCSK9 Inhibitor, Ex-US and China; Lerodalcibep (Lyrokaul®) Approved in the EUhttps://www.pharmaradar360.com/article/oncolytics-biotech-announces-progress-in-reo-033-trial-site-activations-and-fda-bb2648098477d3e8PharmaRadar360en2026-09-28T13:40:00.000ZOncolytics Biotech Announces Progress in REO 033 Trial, Site Activations and FDA-Aligned Pathway for Pelareorep in Metastatic Colorectal Cancerhttps://www.pharmaradar360.com/article/council-backs-major-overhaul-of-eu-pharmaceutical-rules-4b7d1348205d7f9aPharmaRadar360en2026-09-28T13:37:57.000ZCouncil Backs Major Overhaul of EU Pharmaceutical Ruleshttps://www.pharmaradar360.com/article/core-advanced-credentialing-lessons-from-a-hospital-pilot-programme-7779229f5d264d7dPharmaRadar360en2026-09-28T13:36:57.000ZCore advanced credentialing: lessons from a hospital pilot programmehttps://www.pharmaradar360.com/article/mirum-posts-phase-3-hepatitis-win-for-commercially-differentiated-challenger-to-6406fec6953b3111PharmaRadar360en2026-09-28T13:36:17.000ZMirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Virhttps://www.pharmaradar360.com/article/oncolytics-biotech-reports-accelerating-enrollment-in-randomized-reo-033-ras-mut-5648e5ead6976736PharmaRadar360en2026-09-28T13:34:59.000ZOncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Studyhttps://www.pharmaradar360.com/article/kenya-to-manufacture-new-once-monthly-hiv-prevention-pill-key-things-to-know-abo-fe80c895e2923ff3PharmaRadar360en2026-09-28T13:32:22.000ZKenya to manufacture new once-monthly HIV prevention pill: Key things to know about this dealhttps://www.pharmaradar360.com/article/fda-hearing-on-psychedelics-concerns-but-overwhelmingly-positive-251f07e4cb827b18PharmaRadar360en2026-09-28T13:31:03.000ZFDA Hearing on Psychedelics: Concerns, But Overwhelmingly Positivehttps://www.pharmaradar360.com/article/abbvie-wins-fda-nod-for-parkinson-s-disease-drug-20086af8eafc60f9PharmaRadar360en2026-09-28T13:31:01.000ZAbbVie wins FDA nod for Parkinson’s disease drughttps://www.pharmaradar360.com/article/biotech-company-more-than-triples-new-haven-hq-space-bb59ed30932c450ePharmaRadar360en2026-09-28T13:30:01.000ZBiotech company more than triples New Haven HQ spacehttps://www.pharmaradar360.com/article/scynexis-bags-214m-barda-contract-for-antifungal-development-51009f0179a8ef7dPharmaRadar360en2026-09-28T13:29:32.000ZScynexis bags $214M BARDA contract for antifungal developmenthttps://www.pharmaradar360.com/article/biotech-act-europe-is-holding-back-its-food-biotech-leaders-887cf9976dd26ce8PharmaRadar360en2026-09-28T13:27:06.000ZBiotech Act: Europe is holding back its food biotech leadershttps://www.pharmaradar360.com/article/u-s-fda-approves-abbvie-s-juvmo-for-parkinson-s-disease-8e32bc4dacb923c8PharmaRadar360en2026-09-28T13:26:03.000ZU.S. FDA Approves AbbVie's JUVMO for Parkinson's Diseasehttps://www.pharmaradar360.com/article/viking-therapeutics-vktx-vk2735-data-look-strong-but-cash-burn-still-matters-5c4dab01dcd150cePharmaRadar360en2026-09-28T13:19:11.000ZViking Therapeutics (VKTX): VK2735 Data Look Strong, but Cash Burn Still Mattershttps://www.pharmaradar360.com/article/q-a-will-national-licensure-simplify-distributor-compliance-8b7c960ee55c6136PharmaRadar360en2026-09-28T13:18:40.000ZQ&A: Will National Licensure Simplify Distributor Compliance?https://www.pharmaradar360.com/article/independent-review-into-maternity-and-neonatal-services-at-leeds-teaching-hospit-ed0c3079210d1dfaPharmaRadar360en2026-09-28T13:17:05.000ZIndependent review into maternity and neonatal services at Leeds Teaching Hospitals NHS Trust: terms of referencehttps://www.pharmaradar360.com/article/atebrioz-becomes-third-fda-approved-drug-for-rare-fop-offering-a-daily-pill-for-bc3d9a47479f21c2PharmaRadar360en2026-09-28T13:15:38.000ZAtebrioz Becomes Third FDA-Approved Drug for Rare FOP, Offering a Daily Pill for Patients 12 and Olderhttps://www.pharmaradar360.com/article/european-pharmaceutical-review-issue-2-2026-b8f3c4499892e70ePharmaRadar360en2026-09-28T13:13:41.000ZEuropean Pharmaceutical Review Issue 2 2026https://www.pharmaradar360.com/article/tolerance-bio-licenses-tanabe-s-anti-il-33-thymus-antibody-120d1e290bd2208aPharmaRadar360en2026-09-28T13:12:10.000ZTolerance Bio Licenses Tanabe's Anti-IL-33 Thymus Antibodyhttps://www.pharmaradar360.com/article/the-hidden-cost-of-drug-law-federalism-how-state-drug-reforms-could-mislead-cons-fb277680dbe64693PharmaRadar360en2026-09-28T13:10:14.000ZThe Hidden Cost of Drug Law Federalism: How State Drug Reforms Could Mislead Consumershttps://www.pharmaradar360.com/article/dme-drug-remigromig-hits-primary-end-point-in-phase-3-trial-2b3bfc514ea92b41PharmaRadar360en2026-09-28T13:09:34.000ZDME Drug Remigromig Hits Primary End Point in Phase 3 Trialhttps://www.pharmaradar360.com/article/l-b-bohle-to-exhibit-qbcon-1-at-cphi-milan-2026-0d45cf4d62522d1fPharmaRadar360en2026-09-28T13:01:23.000ZL.B. Bohle to exhibit QbCon 1 at CPHI Milan 2026https://www.pharmaradar360.com/article/nonclinical-testing-rulemaking-update-fda-encourages-adoption-of-nams-over-anima-0edb8a5a9c4bd9d3PharmaRadar360en2026-09-28T13:00:56.000ZNonclinical Testing Rulemaking Update: FDA Encourages Adoption of NAMs Over Animal Testshttps://www.pharmaradar360.com/article/lilly-s-olumiant-gains-us-approval-for-adolescents-with-severe-alopecia-276f1ed243a2333ePharmaRadar360en2026-09-28T12:52:09.000ZLilly’s Olumiant gains US approval for adolescents with severe alopeciahttps://www.pharmaradar360.com/article/swiss-groups-seek-reforms-as-clinical-trial-numbers-fall-cec8ebe5f8687055PharmaRadar360en2026-09-28T12:52:07.000ZSwiss groups seek reforms as clinical trial numbers fallhttps://www.pharmaradar360.com/article/merck-and-daiichi-withdraw-us-filing-for-lung-cancer-adc-0b22f39971e507c2PharmaRadar360en2026-09-28T12:52:05.000ZMerck and Daiichi withdraw US filing for lung cancer ADChttps://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-22878ba5448174fdPharmaRadar360en2026-09-28T12:48:57.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/hlb-s-fda-approved-acquired-bile-duct-drug-f6c68694d93cb7e4PharmaRadar360en2026-09-28T12:42:51.000ZHLB's FDA-Approved Acquired Bile Duct Drughttps://www.pharmaradar360.com/article/4d-molecular-starts-phase-3-trial-for-diabetic-eye-disease-drug-2ef4db146444b3a9PharmaRadar360en2026-09-28T12:37:59.000Z4D Molecular starts Phase 3 trial for diabetic eye disease drughttps://www.pharmaradar360.com/article/kodiak-s-stock-doubles-as-resurrected-eye-disease-drug-matches-eylea-in-phase-3-d6a5f93ce6bf26ebPharmaRadar360en2026-09-28T12:37:34.000ZKodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3https://www.pharmaradar360.com/article/tukaram-mundhe-on-sanjay-raut-s-extortion-charges-show-me-8bccee53c5869252PharmaRadar360en2026-09-28T12:37:08.000ZTukaram Mundhe on Sanjay Raut’s extortion charges: ‘Show me’https://www.pharmaradar360.com/article/micro-rmm-in-depth-focus-dc20160d4995f131PharmaRadar360en2026-09-28T12:32:28.000ZMicro/RMM In-Depth Focushttps://www.pharmaradar360.com/article/abbvie-lands-fda-approval-for-next-generation-parkinson-s-drug-juvmo-39527c2cb61bb6cdPharmaRadar360en2026-09-28T12:17:09.000ZAbbVie lands FDA approval for next-generation Parkinson’s drug, Juvmohttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-legend-biotech-stock-rating-on-durability-data-f286c6567812a7efPharmaRadar360en2026-09-28T12:15:28.000ZH.C. Wainwright reiterates Legend Biotech stock rating on durability datahttps://www.pharmaradar360.com/article/eutecma-acquires-tempaid-creating-a-cold-chain-packaging-business-that-spans-pal-ac33bf7eb02a830bPharmaRadar360en2026-09-28T12:01:02.000Zeutecma Acquires Tempaid, Creating a Cold Chain Packaging Business That Spans Pallet to Parcel Across Europe, North America and Asiahttps://www.pharmaradar360.com/article/bd-alaristm-pump-module-and-subset-of-compatible-pump-infusion-sets-72f10cac91bc3e72PharmaRadar360en2026-09-28T12:00:00.000ZBD Alaris™ Pump Module and subset of Compatible Pump Infusion Setshttps://www.pharmaradar360.com/article/new-approach-methodologies-in-safety-and-toxicology-testing-why-proving-repeatab-41fd57b4f898f978PharmaRadar360en2026-09-28T12:00:00.000ZNew approach methodologies in safety and toxicology testing: Why proving repeatability is the next hurdle for widespread adoptionhttps://www.pharmaradar360.com/article/a-9-person-study-reported-61-lower-injection-burden-with-4d-150-versus-a-13-shot-dd9ddbd42d954b9ePharmaRadar360en2026-09-28T12:00:00.000ZA 9-person study reported 61% lower injection burden with 4D-150 versus a 13-shot projection.https://www.pharmaradar360.com/article/an-experimental-hepatitis-d-drug-met-virus-and-liver-targets-in-56-of-patients-n-7bc6d52ec847246aPharmaRadar360en2026-09-28T12:00:00.000ZAn experimental hepatitis D drug met virus and liver targets in 56% of patients; none in the delayed-treatment group did.https://www.pharmaradar360.com/article/one-patient-s-brain-tumor-shrank-about-60-on-an-experimental-drug-it-stayed-cont-9c3f1f0037579346PharmaRadar360en2026-09-28T12:00:00.000ZOne patient's brain tumor shrank about 60% on an experimental drug. It stayed controlled through 21 months of treatment.https://www.pharmaradar360.com/article/a-patient-receives-an-experimental-prostate-cancer-scan-the-later-phase-is-expec-14ee0ad35635acfbPharmaRadar360en2026-09-28T12:00:00.000ZA patient receives an experimental prostate cancer scan; the later phase is expected to enroll about 400.https://www.pharmaradar360.com/article/u-s-fda-approves-abbvie-s-juvmotm-tavapadon-for-parkinson-s-disease-85c3d73187d36229PharmaRadar360en2026-09-28T12:00:00.000ZU.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Diseasehttps://www.pharmaradar360.com/article/cullinan-therapeutics-inc-common-stock-cgem-stock-price-news-quote-history-9e08eae6d576bb60PharmaRadar360en2026-09-28T11:58:00.000ZCullinan Therapeutics, Inc. - Common Stock (CGEM) Stock Price, News, Quote & Historyhttps://www.pharmaradar360.com/article/c-f-expert-co-authors-research-on-unified-namespace-architecture-for-pharmaceuti-d28ce3f3ad408e44PharmaRadar360en2026-09-28T11:55:00.000ZC&F Expert Co-Authors Research on Unified Namespace Architecture for Pharmaceutical Manufacturinghttps://www.pharmaradar360.com/article/antibiotic-awareness-quizzes-and-crosswords-71822894dcfe3582PharmaRadar360en2026-09-28T11:38:22.000ZAntibiotic awareness: quizzes and crosswordshttps://www.pharmaradar360.com/article/cphi-milan-how-usp-will-shape-procurement-decisions-b14e93c09a838523PharmaRadar360en2026-09-28T11:33:09.000ZCPHI Milan: How USP Will Shape Procurement Decisionshttps://www.pharmaradar360.com/article/gram-negative-mrsa-and-mssa-bacteraemia-and-c-difficile-infections-quarterly-rep-3d7ee476362d26c5PharmaRadar360en2026-09-28T11:27:51.000ZGram-negative, MRSA and MSSA bacteraemia and C. difficile infections: quarterly reportshttps://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-b9269baea09c3043PharmaRadar360en2026-09-28T11:27:41.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly datahttps://www.pharmaradar360.com/article/accessing-ukhsa-protected-data-4faf8d17ef53c227PharmaRadar360en2026-09-28T11:24:30.000ZAccessing UKHSA protected datahttps://www.pharmaradar360.com/article/hilo-s-wearable-blood-pressure-monitor-to-help-with-hypertension-a0ca74e3d563b332PharmaRadar360en2026-09-28T11:22:41.000ZHilo’s wearable blood pressure monitor to help with hypertensionhttps://www.pharmaradar360.com/article/good-science-is-not-enough-k4-mst-to-explore-at-us-biotech-day-what-makes-a-biot-efc804d4e188e8faPharmaRadar360en2026-09-28T11:16:35.000ZGood Science Is Not Enough: K4-MST To Explore At US BioTech Day, What Makes a Biotech Company Investablehttps://www.pharmaradar360.com/article/covid-19-test-approval-how-to-apply-b80697357930ff11PharmaRadar360en2026-09-28T11:15:19.000ZCOVID-19 test approval: how to applyhttps://www.pharmaradar360.com/article/4basebio-and-trilink-biotechnologies-partner-to-advance-leading-pharmaceutical-c-82a4e909e515f5baPharmaRadar360en2026-09-28T11:10:28.000Z4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company’s Phase I Cell Therapy Programhttps://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-2026-to-2027-quarterly-da-c123be05410e88f7PharmaRadar360en2026-09-28T11:09:38.000ZCover of vaccination evaluated rapidly (COVER) programme 2026 to 2027: quarterly datahttps://www.pharmaradar360.com/article/tiziana-life-sciences-announces-first-participants-dosed-in-als-banyan-clinical-a7a07412ea581575PharmaRadar360en2026-09-28T11:00:00.000ZTiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumabhttps://www.pharmaradar360.com/article/a-52-week-acne-trial-in-china-showed-further-improvement-across-all-secondary-me-fadb1049d93aa7afPharmaRadar360en2026-09-28T11:00:00.000ZA 52-week acne trial in China showed further improvement across all secondary measures.https://www.pharmaradar360.com/article/pharmazz-completes-enrollment-in-160-patient-phase-4-trial-of-sovateltide-in-acu-021b29c8f3061d05PharmaRadar360en2026-09-28T11:00:00.000ZPharmazz Completes Enrollment in 160-Patient Phase 4 Trial of Sovateltide in Acute Ischemic Strokehttps://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-476c46b5e267deccPharmaRadar360en2026-09-28T10:54:20.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to April to June 2026https://www.pharmaradar360.com/article/when-the-primary-endpoint-moves-after-283-patients-are-already-in-183098d238999e77PharmaRadar360en2026-09-28T10:48:52.000ZWhen the Primary Endpoint Moves After 283 Patients Are Already Inhttps://www.pharmaradar360.com/article/pharmaceutical-retailers-stock-performance-17ac5732ce635e1bPharmaRadar360en2026-09-28T10:48:25.000ZPharmaceutical Retailers Stock Performancehttps://www.pharmaradar360.com/article/tuberculosis-in-england-national-quarterly-report-q3-2026-410286263e6b406dPharmaRadar360en2026-09-28T10:48:09.000ZTuberculosis in England national quarterly report: Q3 2026https://www.pharmaradar360.com/article/cuba-phase-3-clinical-trial-of-jusvinza-shows-efficacy-in-patients-with-arthriti-70bcc80789600855PharmaRadar360en2026-09-28T10:46:47.000ZCuba: Phase 3 clinical trial of Jusvinza shows efficacy in patients with arthritis following Chikungunya infectionhttps://www.pharmaradar360.com/article/merck-enters-into-exclusive-global-license-agreement-with-scibrunch-therapeutics-b5bd3806e53be283PharmaRadar360en2026-09-28T10:45:00.000ZMerck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitorhttps://www.pharmaradar360.com/article/pfizer-advances-today-s-cancer-care-and-tomorrow-s-potential-breakthroughs-at-es-b3cc41e797486f65PharmaRadar360en2026-09-28T10:45:00.000ZPfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMOhttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-44-report-data-to-week-43-dat-34f205820f4e2f50PharmaRadar360en2026-09-28T10:36:48.000ZNational flu and COVID-19 surveillance report, week 44 report: data to week 43 (data up to 25 October 2026)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-25-october-2026-1906a72e779baed3PharmaRadar360en2026-09-28T10:36:39.000ZWeekly all-cause mortality surveillance: week ending 25 October 2026https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-44-report-data-to-week-43-data-up-t-2ed6b23c58ef4d92PharmaRadar360en2026-09-28T10:36:31.000ZNational Norovirus and Rotavirus Report, week 44 report: data to week 43 (data up to 25 October 2026)https://www.pharmaradar360.com/article/l-oreal-backs-shanghai-biotech-moyom-s-push-beyond-china-7478a49fd7852167PharmaRadar360en2026-09-28T10:31:42.000ZL'Oréal backs Shanghai biotech Moyom's push beyond Chinahttps://www.pharmaradar360.com/article/kenya-strengthens-local-pharmaceutical-production-for-health-security-5b030eb8ed43bd72PharmaRadar360en2026-09-28T10:31:01.000ZKenya strengthens local pharmaceutical production for health securityhttps://www.pharmaradar360.com/article/in-a-vision-trial-54-of-patients-went-six-months-between-eye-treatments-93a218f57580de65PharmaRadar360en2026-09-28T10:30:00.000ZIn a vision trial, 54% of patients went six months between eye treatmentshttps://www.pharmaradar360.com/article/astellas-launches-phase-3-trial-of-kras-g12d-targeted-drug-in-advanced-lung-canc-8929bcbb11641b13PharmaRadar360en2026-09-28T10:17:33.000ZAstellas launches Phase 3 trial of KRAS G12D-targeted drug in advanced lung cancerhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-s-sys6077-injection-obtains-clinical-trial-approval-in-china-8e2c578b10c6b8b3PharmaRadar360en2026-09-28T10:16:56.000ZCspc Pharmaceutical's Sys6077 Injection Obtains Clinical Trial Approval In Chinahttps://www.pharmaradar360.com/article/fda-approves-lyrfigtu-as-second-line-treatment-option-for-certain-bile-duct-canc-42d37061656560a7PharmaRadar360en2026-09-28T10:07:51.000ZFDA approves Lyrfigtu as second-line treatment option for certain bile duct cancer patientshttps://www.pharmaradar360.com/article/medicinova-announces-topline-results-from-mn-001-natg-202-clinical-trial-of-mn-0-f59ad417e09f08efPharmaRadar360en2026-09-28T10:07:20.000ZMediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)https://www.pharmaradar360.com/article/kodiak-sciences-kod-shares-rise-7-ahead-of-daybreak-phase-3-t-860ada3bfee18035PharmaRadar360en2026-09-28T10:07:12.000ZKodiak Sciences (KOD) Shares Rise 7% Ahead of DAYBREAK Phase 3 Thttps://www.pharmaradar360.com/article/your-questions-answered-two-fda-approvals-six-platform-deals-and-a-european-warn-7bc67f3ff2400bcePharmaRadar360en2026-09-28T10:05:53.000ZYour Questions Answered: Two FDA Approvals, Six Platform Deals, and a European Warninghttps://www.pharmaradar360.com/article/rethinking-biotech-investment-and-innovation-in-a-productivity-driven-era-029a037f2b018024PharmaRadar360en2026-09-28T10:04:10.000ZRethinking biotech investment and innovation in a productivity-driven erahttps://www.pharmaradar360.com/article/zymeworks-announces-updated-2026-financial-guidance-and-final-transaction-detail-c0060916b3867e4cPharmaRadar360en2026-09-28T10:02:27.000ZZymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisitionhttps://www.pharmaradar360.com/article/a-40-person-study-found-more-good-cholesterol-with-medicinova-s-drug-but-no-sign-91c52abbd0e62b08PharmaRadar360en2026-09-28T10:00:00.000ZA 40-person study found more “good” cholesterol with MediciNova's drug, but no significant liver-fat difference.https://www.pharmaradar360.com/article/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverag-6e6d18fe6a6a0b49PharmaRadar360en2026-09-28T10:00:00.000ZCodexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNAhttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-nov-952379824a474647PharmaRadar360en2026-09-28T09:54:05.000ZRespiratory syncytial virus (RSV) older adults vaccination coverage in England: November 2026 reporthttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-august-ad8ccd3192ac2329PharmaRadar360en2026-09-28T09:53:42.000ZRespiratory syncytial virus (RSV) maternal vaccination coverage in England: August 2026 reporthttps://www.pharmaradar360.com/article/moyom-biotech-secures-financing-from-cathay-capital-to-accelerate-global-growth-38fb609f57ea578cPharmaRadar360en2026-09-28T09:47:03.000ZMOYOM Biotech Secures Financing from Cathay Capital to Accelerate Global Growth in Regenerative Aestheticshttps://www.pharmaradar360.com/article/medicamen-biotech-shareholders-approve-all-agm-resolutions-0b170074eb47155ePharmaRadar360en2026-09-28T09:44:48.000ZMedicamen Biotech shareholders approve all AGM resolutionshttps://www.pharmaradar360.com/article/sartorius-stedim-biotech-stock-breaks-through-its-215-80-resistance-and-accelera-fcc4b995a20c828bPharmaRadar360en2026-09-28T09:43:00.000ZSartorius Stedim Biotech Stock Breaks Through its 215.80 € Resistance and Accelerateshttps://www.pharmaradar360.com/article/moyom-biotech-secures-financing-from-cathay-capital-to-accelerate-global-growth-612ae4921bdf2d20PharmaRadar360en2026-09-28T09:42:00.000ZMOYOM Biotech Secures Financing from Cathay Capital to Accelerate Global Growth in Regenerative Aestheticshttps://www.pharmaradar360.com/article/fake-drug-case-prashanth-ranjan-babu-arrested-at-b-luru-airport-nation-a8b4b9545479112ePharmaRadar360en2026-09-28T09:35:34.000ZFake Drug Case: Prashanth Ranjan Babu Arrested At B'luru Airport | Nationhttps://www.pharmaradar360.com/article/legend-biotech-legn-on-carvykti-follow-up-data-and-the-case-for-a-reset-valuatio-825e9840444976bdPharmaRadar360en2026-09-28T09:33:59.000ZLegend Biotech (LEGN) On CARVYKTI Follow Up Data And The Case For A Reset Valuationhttps://www.pharmaradar360.com/article/six-spanish-biotech-startups-to-watch-in-2026-2522439a14b2707cPharmaRadar360en2026-09-28T09:21:49.000ZSix Spanish biotech startups to watch in 2026https://www.pharmaradar360.com/article/cheshire-biotech-makes-strong-progress-in-treatment-of-addiction-and-other-disor-a1f240dae6ed6119PharmaRadar360en2026-09-28T09:13:10.000ZCheshire biotech makes strong progress in treatment of addiction and other disordershttps://www.pharmaradar360.com/article/apac-biotech-ipos-of-2026-who-listed-what-it-raised-where-it-trades-now-126880b30ac78154PharmaRadar360en2026-09-28T09:12:58.000ZAPAC Biotech IPOs of 2026: Who Listed, What It Raised, Where It Trades Nowhttps://www.pharmaradar360.com/article/ebola-and-marburg-returning-workers-scheme-rws-0b1c8da0eb5eb1f7PharmaRadar360en2026-09-28T09:00:04.000ZEbola and Marburg: returning workers scheme (RWS)https://www.pharmaradar360.com/article/medical-radiation-patient-doses-fc5e1e504e3cf66cPharmaRadar360en2026-09-28T08:51:40.000ZMedical radiation: patient doseshttps://www.pharmaradar360.com/article/nuclear-emergencies-information-for-the-public-4b3a1704930ba323PharmaRadar360en2026-09-28T08:51:28.000ZNuclear emergencies: information for the publichttps://www.pharmaradar360.com/article/ionising-radiation-dose-comparisons-e62d6734170184b3PharmaRadar360en2026-09-28T08:51:15.000ZIonising radiation: dose comparisonshttps://www.pharmaradar360.com/article/ono-pharmaceutical-co-to-go-ex-dividend-on-september-29th-2026-with-0-352-usd-di-016fe8f200e1780ePharmaRadar360en2026-09-28T08:37:51.000ZONO PHARMACEUTICAL CO To Go Ex-Dividend On September 29th, 2026 With 0.352 USD Dividend Per Sharehttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-is-back-in-the-spotlight-what-is-catching-atten-4a815942faeef10fPharmaRadar360en2026-09-28T08:34:27.000ZWest Pharmaceutical Services (WST) Is Back In The Spotlight, What Is Catching Attention?https://www.pharmaradar360.com/article/slowing-down-aging-extending-drug-action-and-new-molecules-recent-scientific-inv-7b62b25d8e9163bfPharmaRadar360en2026-09-28T08:33:55.000ZSlowing down aging, extending drug action, and new molecules: recent scientific inventions for the pharmaceutical industryhttps://www.pharmaradar360.com/article/samsung-pharmaceutical-announced-on-the-28th-that-it-has-submitted-a-phase-2b-3-0e72f1a0691a1feaPharmaRadar360en2026-09-28T08:30:08.000ZSamsung Pharmaceutical announced on the 28th that it has submitted a phase 2b/3 clinical trial planhttps://www.pharmaradar360.com/article/merck-daiichi-pull-lung-cancer-filing-after-fda-pushback-deals-another-blow-to-4-0cf0f2b07ca099dePharmaRadar360en2026-09-28T08:30:00.000ZMerck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B dealhttps://www.pharmaradar360.com/article/medicines-apply-for-a-variation-to-your-marketing-authorisation-7e5ad9f93903f719PharmaRadar360en2026-09-28T08:25:33.000ZMedicines: apply for a variation to your marketing authorisationhttps://www.pharmaradar360.com/article/pharma-package-council-adopts-new-rules-for-a-fairer-and-more-competitive-eu-pha-64801fc4dfaf1151PharmaRadar360en2026-09-28T08:24:16.000Z‘Pharma package’: Council adopts new rules for a fairer and more competitive EU pharmaceutical sectorhttps://www.pharmaradar360.com/article/adult-social-care-survey-england-2025-to-2026-report-9053469da7332a96PharmaRadar360en2026-09-28T08:22:34.000ZAdult social care survey, England: 2025 to 2026 reporthttps://www.pharmaradar360.com/article/fda-approves-mirum-s-oral-drug-for-rare-disease-fop-472ed53fcb60cab4PharmaRadar360en2026-09-28T08:03:01.000ZFDA approves Mirum's oral drug for rare disease FOPhttps://www.pharmaradar360.com/article/can-this-biotech-innovation-halt-the-destructive-march-of-a-cereal-killer-7ad8150920272c7fPharmaRadar360en2026-09-28T08:02:58.000ZCan this biotech innovation halt the destructive march of a cereal killer?https://www.pharmaradar360.com/article/mrna-stock-eyes-best-year-ever-analyst-calls-china-s-ai-drug-lead-baseless-as-mo-c98c91e0d5349a92PharmaRadar360en2026-09-28T07:59:02.000ZMRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Cancer Datahttps://www.pharmaradar360.com/article/sanjay-raut-praises-maha-fda-crackdown-but-warns-mundhe-of-alleged-extortion-a904b746289b299aPharmaRadar360en2026-09-28T07:53:23.000ZSanjay Raut praises Maha FDA crackdown, but warns Mundhe of alleged extortionhttps://www.pharmaradar360.com/article/2026-f5963eb9b39a04fcPharmaRadar360en2026-09-28T07:51:51.000ZΣτοιχεία εκτέλεσης προϋπολογισμού μηνός Αυγούστου 2026https://www.pharmaradar360.com/article/dutch-minister-herbert-presented-with-national-plan-for-medical-biotech-by-vig-38c5c7e76f26fe1ePharmaRadar360en2026-09-28T07:51:12.000ZDutch Minister Herbert presented with national plan for medical biotech by VIGhttps://www.pharmaradar360.com/article/why-singapore-is-a-top-choice-for-biopharma-firms-seeking-global-expansion-20356f895d95ac34PharmaRadar360en2026-09-28T07:48:05.000ZWhy Singapore is a top choice for biopharma firms seeking global expansionhttps://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-35523ec4937619f8PharmaRadar360en2026-09-28T07:40:41.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, August 2025 to August 2026https://www.pharmaradar360.com/article/the-willow-trial-didn-t-fail-enpatoran-the-endpoint-did-0c05981301b69fb0PharmaRadar360en2026-09-28T07:33:52.000ZThe WILLOW Trial Didn’t Fail Enpatoran. The Endpoint Did.https://www.pharmaradar360.com/article/lupin-wins-tentative-us-fda-approval-for-apixaban-oral-suspension-a13c8823cd4c467fPharmaRadar360en2026-09-28T07:27:02.000ZLupin wins tentative US FDA approval for apixaban oral suspensionhttps://www.pharmaradar360.com/article/fda-extends-relutrigine-review-delays-pdufa-to-december-9d96ebb00256093fPharmaRadar360en2026-09-28T07:15:08.000ZFDA Extends Relutrigine Review, Delays PDUFA to Decemberhttps://www.pharmaradar360.com/article/innovent-biologics-expands-phase-3-lung-cancer-trial-globally-2e6dedabcfe456b2PharmaRadar360en2026-09-28T07:12:04.000ZInnovent Biologics expands Phase 3 lung cancer trial globallyhttps://www.pharmaradar360.com/article/chugai-pharmaceutical-co-ltd-regarding-discontinuation-of-development-of-gym329-670a2c2aa3c7e56ePharmaRadar360en2026-09-28T07:04:32.000ZChugai Pharmaceutical Co Ltd - Regarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMAhttps://www.pharmaradar360.com/article/pli-schemes-boost-india-s-pharma-bulk-drugs-and-medical-devices-manufacturing-496fb55060704538PharmaRadar360en2026-09-28T07:04:05.000ZPLI schemes boost India’s pharma, bulk drugs and medical devices manufacturinghttps://www.pharmaradar360.com/article/how-tanzania-plans-to-slash-1-billion-pharmaceutical-bill-55bd44b6b716a671PharmaRadar360en2026-09-28T07:03:01.000ZHow Tanzania plans to slash $1 billion pharmaceutical billhttps://www.pharmaradar360.com/article/us-grants-india-tariff-relief-on-specialty-drugs-b25bb370201a054aPharmaRadar360en2026-09-28T07:02:56.000ZUS grants India tariff relief on specialty drugshttps://www.pharmaradar360.com/article/technology-transfer-the-hidden-bottleneck-in-pharmaceutical-value-realisation-1a9ff4f4fab38107PharmaRadar360en2026-09-28T07:02:43.000ZTechnology transfer: the hidden bottleneck in pharmaceutical value realisationhttps://www.pharmaradar360.com/article/gym329-emugrobart-sma-228f48bd5b027da6PharmaRadar360en2026-09-28T07:00:00.000ZGYM329 (emugrobart) の肥満症開発中止、ライセンス返還およびSMA開発再開に関するお知らせhttps://www.pharmaradar360.com/article/notice-regarding-discontinuation-of-development-of-gym329-emugrobart-for-obesity-2264045a47cfed2aPharmaRadar360en2026-09-28T07:00:00.000ZNotice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMAhttps://www.pharmaradar360.com/article/insmed-insm-gets-faster-fda-review-can-its-lung-drug-reach-more-patients-054d9e61c5fda138PharmaRadar360en2026-09-28T06:42:18.000ZInsmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?https://www.pharmaradar360.com/article/emirates-biotech-and-uaeu-to-build-uae-s-first-waste-to-biogas-plant-29e54d77413695fcPharmaRadar360en2026-09-28T06:40:39.000ZEmirates Biotech and UAEU to build UAE’s first waste-to-biogas planthttps://www.pharmaradar360.com/article/innovent-expands-phase-3-marslight-11-trial-of-ibi363-tak-928-to-non-squamous-ns-64867ac1fd3d2b15PharmaRadar360en2026-09-28T06:38:51.000ZInnovent Expands Phase 3 MarsLight-11 Trial of IBI363/TAK-928 to Non-Squamous NSCLChttps://www.pharmaradar360.com/article/inventiva-s-lanifibranor-faces-cash-runway-pressure-before-phase-3-mash-data-086283b84290fcbfPharmaRadar360en2026-09-28T06:38:51.000ZInventiva’s Lanifibranor Faces Cash Runway Pressure Before Phase 3 MASH Datahttps://www.pharmaradar360.com/article/akeso-enrolls-first-patient-in-phase-iii-trial-of-cadonilimab-vs-nivolumab-for-g-18d5998783d23da2PharmaRadar360en2026-09-28T06:38:51.000ZAkeso Enrolls First Patient in Phase III Trial of Cadonilimab vs Nivolumab for Gastric Cancerhttps://www.pharmaradar360.com/article/korea-exchange-speeds-biotech-ipo-reviews-with-sector-expertise-657f4da20d197313PharmaRadar360en2026-09-28T06:09:17.000ZKorea Exchange speeds biotech IPO reviews with sector expertisehttps://www.pharmaradar360.com/article/inventiva-reports-unaudited-2026-first-half-financial-results-and-provides-corpo-0db0ba223fe8df78PharmaRadar360en2026-09-28T06:05:12.000ZInventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Updatehttps://www.pharmaradar360.com/article/ose-immunotherapeutics-q2fy26-results-cash-at-11-1-million-runway-to-dec-bbd9516b55299544PharmaRadar360en2026-09-28T06:04:51.000ZOSE Immunotherapeutics Q2FY26 Results: Cash at €11.1 million, runway to Dechttps://www.pharmaradar360.com/article/4basebio-plc-4basebio-and-trilink-biotechnologies-partner-to-advance-leading-pha-a49d6d6b2b506aa8PharmaRadar360en2026-09-28T06:03:17.000Z4basebio Plc - 4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company's Phase I Cell Therapy Programhttps://www.pharmaradar360.com/article/this-is-ipsen-b11cb2828584852bPharmaRadar360en2026-09-28T06:01:18.000ZThis is Ipsenhttps://www.pharmaradar360.com/article/big-fda-allegations-is-food-on-your-plate-really-safe-48cc109be1e35976PharmaRadar360en2026-09-28T05:54:58.000ZBig FDA Allegations : Is Food on Your Plate Really Safe?https://www.pharmaradar360.com/article/paradigm-biopharmaceuticals-extends-voluntary-suspension-pending-phase-3-trial-d-662ab46f55889d32PharmaRadar360en2026-09-28T05:54:35.000ZParadigm Biopharmaceuticals Extends Voluntary Suspension Pending Phase 3 Trial Data Reviewhttps://www.pharmaradar360.com/article/ose-immunotherapeutics-reports-its-cash-position-as-of-june-30-2026-and-provides-8453d47a72282ec5PharmaRadar360en2026-09-28T05:44:53.000ZOSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Updatehttps://www.pharmaradar360.com/article/daewoong-pharmaceutical-leads-south-korea-ai-platform-to-design-drug-formulation-f2d4d941317b509ePharmaRadar360en2026-09-28T05:35:00.000ZDaewoong Pharmaceutical leads South Korea AI platform to design drug formulations - CHOSUNBIZhttps://www.pharmaradar360.com/article/empowering-biotech-innovation-in-asia-pacific-d2e89bff38dee53aPharmaRadar360en2026-09-28T05:20:51.000ZEmpowering Biotech Innovation in Asia-Pacifichttps://www.pharmaradar360.com/article/is-celcuity-celc-stock-a-buy-56d158e8a4b7b7b0PharmaRadar360en2026-09-28T04:59:00.000ZIs Celcuity (CELC) Stock a Buy?https://www.pharmaradar360.com/article/video-europe-looks-for-a-prescription-to-clean-up-the-baltic-299ad15e601a2814PharmaRadar360en2026-09-28T04:57:43.000ZVideo. Europe looks for a prescription to clean up the Baltichttps://www.pharmaradar360.com/article/europe-looks-for-a-prescription-to-clean-up-the-baltic-30f96d24dacc25a0PharmaRadar360en2026-09-28T04:57:43.000ZEurope looks for a prescription to clean up the Baltichttps://www.pharmaradar360.com/article/us-fda-approves-mirum-s-drug-for-rare-bone-disorder-82df07ef4095d83dPharmaRadar360en2026-09-28T04:56:00.000ZUS FDA approves Mirum’s drug for rare bone disorderhttps://www.pharmaradar360.com/article/realmind-biotech-raises-7-4m-series-c-moves-diagnostics-production-to-huangshan-0d9fb58e7bd1da6cPharmaRadar360en2026-09-28T04:46:20.000ZRealmind Biotech raises $7.4M Series C, moves diagnostics production to Huangshanhttps://www.pharmaradar360.com/article/interview-long-term-tagrisso-survival-benefit-raises-stakes-for-early-egfr-testi-002a2163afdece23PharmaRadar360en2026-09-28T04:38:28.000Z[Interview] Long-term Tagrisso survival benefit raises stakes for early EGFR testinghttps://www.pharmaradar360.com/article/new-thermo-fisher-scientific-drug-facility-for-vaccine-manufacture-opens-in-sing-fd85d4b848aa6fd2PharmaRadar360en2026-09-28T04:30:27.000ZNew Thermo Fisher Scientific drug facility for vaccine manufacture opens in Singaporehttps://www.pharmaradar360.com/article/ifinatamab-deruxtecan-biologics-license-application-for-certain-patients-with-pr-ce88efa9ecf2bb2ePharmaRadar360en2026-09-28T04:22:37.000ZIfinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawnhttps://www.pharmaradar360.com/article/ai-clinical-monitoring-tool-saves-millions-in-trial-costs-5e560f99c3f6387bPharmaRadar360en2026-09-28T04:14:33.000ZAI Clinical Monitoring Tool Saves Millions in Trial Costshttps://www.pharmaradar360.com/article/emirates-biotech-and-uaeu-launch-first-integrated-organic-waste-valorisation-pil-1f35fb0034039d5aPharmaRadar360en2026-09-28T04:12:06.000ZEmirates Biotech and UAEU launch first integrated organic-waste valorisation pilot planthttps://www.pharmaradar360.com/article/kenya-prepares-to-make-once-a-month-hiv-prevention-pill-as-drug-enters-final-tri-00c46a8ec354079cPharmaRadar360en2026-09-28T04:08:17.000ZKenya prepares to make once-a-month HIV prevention pill as drug enters final trialshttps://www.pharmaradar360.com/article/hong-kong-customs-seizes-suspected-pharmaceutical-products-worth-about-290-000-w-a015bd8992e5f357PharmaRadar360en2026-09-28T03:56:15.000ZHong Kong Customs seizes suspected pharmaceutical products worth about $290,000 (with photo)https://www.pharmaradar360.com/article/us-fda-maintains-clinical-hold-on-patient-enrollment-for-newron-s-phase-3-trial-b95e7075f3ecf9dcPharmaRadar360en2026-09-28T03:36:24.000ZUS FDA Maintains Clinical Hold on Patient Enrollment for Newron's Phase 3 Trial of Schizophrenia Drughttps://www.pharmaradar360.com/article/regyuratorisaiensu-regulatory-science-activity-report-updated-07ad19672c666c08PharmaRadar360en2026-09-28T03:00:00.000Z[REGYURATORISAIENSU]Regulatory Science Activity Report updatedhttps://www.pharmaradar360.com/article/africa-s-medicine-dependency-the-race-to-build-a-homegrown-pharmaceutical-indust-e8767d9d2f2c5d5bPharmaRadar360en2026-09-28T03:00:00.000ZAfrica's medicine dependency: The race to build a homegrown pharmaceutical industryhttps://www.pharmaradar360.com/article/endpoints-news-announces-the-2026-winners-of-the-endpoints-11-awards-showcasing-939d242e4e4afbfaPharmaRadar360en2026-09-28T02:57:44.000ZEndpoints News Announces the 2026 Winners of the Endpoints 11 Awards, showcasing biotech’s most exciting startupshttps://www.pharmaradar360.com/article/bristol-myers-squibb-announces-first-presentation-of-results-for-zenbexustm-iber-1a0cfd5938ff55b5PharmaRadar360en2026-09-28T02:57:43.000ZBristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myelomahttps://www.pharmaradar360.com/article/biotech-new-zealand-launches-engineering-biology-group-ee78f427d5c6cf57PharmaRadar360en2026-09-28T02:51:38.000ZBioTech New Zealand launches engineering biology grouphttps://www.pharmaradar360.com/article/kali-therapeutics-named-to-the-2026-endpoints-11-recognizing-biotech-s-most-prom-c5bf540d1850f357PharmaRadar360en2026-09-28T02:23:41.000ZKali Therapeutics Named to the 2026 Endpoints 11, Recognizing Biotech's Most Promising Startupshttps://www.pharmaradar360.com/article/daewoong-pharmaceutical-expands-ai-into-drug-formulation-design-with-4-million-g-f42f7e25b1fb6befPharmaRadar360en2026-09-28T02:07:00.000ZDaewoong Pharmaceutical Expands AI into Drug Formulation Design with $4 Million Government Projecthttps://www.pharmaradar360.com/article/most-read-kobayashi-pharmaceutical-co-sankei-real-estate-sk-hynix-goodbaby-inter-bca7b5d0f5e96720PharmaRadar360en2026-09-28T02:01:21.000ZMost Read: Kobayashi Pharmaceutical Co, Sankei Real Estate, SK Hynix, Goodbaby International, Yinson Holdings, Dayang Enterprise Hldgs, Tencent, Northern Star Resources and morehttps://www.pharmaradar360.com/article/daewon-pharmaceutical-resumes-cough-syrup-pouch-production-91ac0ee1f83b3f83PharmaRadar360en2026-09-28T01:55:37.000ZDaewon Pharmaceutical Resumes Cough Syrup Pouch Productionhttps://www.pharmaradar360.com/article/fda-seals-packaged-drinking-water-unit-at-lassipora-8083ecc0c470f49fPharmaRadar360en2026-09-28T01:38:06.000ZFDA seals packaged drinking water unit at Lassiporahttps://www.pharmaradar360.com/article/a-cancer-drug-targeting-two-growth-signals-enters-its-first-human-trial-9f14a0d4c79a19f0PharmaRadar360en2026-09-28T01:05:10.000ZA cancer drug targeting two growth signals enters its first human trialhttps://www.pharmaradar360.com/article/adhd-narcotic-medications-prescribed-to-964-children-under-age-6-over-three-year-e303103913c54cebPharmaRadar360en2026-09-28T00:26:37.000ZADHD Narcotic Medications Prescribed to 964 Children Under Age 6 Over Three Yearshttps://www.pharmaradar360.com/article/paradigm-extends-trading-suspension-pending-phase-3-data-review-bb09ec3f56247094PharmaRadar360en2026-09-28T00:20:20.000ZParadigm Extends Trading Suspension Pending Phase 3 Data Reviewhttps://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-4db25c0ec0638cacPharmaRadar360en2026-09-28T00:00:00.000ZNovo Nordisk filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-573a6724e35963c3PharmaRadar360en2026-09-28T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-35fd5d4f916ce9b7PharmaRadar360en2026-09-28T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-4015835aee0b8977PharmaRadar360en2026-09-28T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-dc5dc18073359567PharmaRadar360en2026-09-28T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-bfe6bb38aeac789ePharmaRadar360en2026-09-28T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-c85f74c190edb1a3PharmaRadar360en2026-09-28T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-5634be7750f297faPharmaRadar360en2026-09-28T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-ffc5762810df73a6PharmaRadar360en2026-09-28T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-5e9d8f7c92a8c7a0PharmaRadar360en2026-09-28T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-d67131d364778b08PharmaRadar360en2026-09-28T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-89b0ad013187f971PharmaRadar360en2026-09-28T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-993c41450c99dc4dPharmaRadar360en2026-09-28T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-a442c44405b288a9PharmaRadar360en2026-09-28T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-c57ad3d9cb02b718PharmaRadar360en2026-09-28T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/submission-for-omb-review-30-day-comment-request-0da737e753257b22PharmaRadar360en2026-09-28T00:00:00.000ZSubmission for OMB Review; 30-Day Comment Request;https://www.pharmaradar360.com/article/submission-for-omb-review-30-day-comment-request-generic-clearance-for-nih-citiz-8120dbfec9668c68PharmaRadar360en2026-09-28T00:00:00.000ZSubmission for OMB Review; 30-Day Comment Request; Generic Clearance for NIH Citizen Science and Crowdsourcing Projects (Office of the Director)https://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-irvine-labs-inc-2a6b9f87419434abPharmaRadar360en2026-09-28T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: Irvine Labs, Inc.https://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-cargill-incorporated-bf6aded5705969fcPharmaRadar360en2026-09-28T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: Cargill, Incorporatedhttps://www.pharmaradar360.com/article/importer-of-controlled-substances-application-benuvia-operations-llc-681d89395f14aa29PharmaRadar360en2026-09-28T00:00:00.000ZImporter of Controlled Substances Application: Benuvia Operations, LLChttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-6d8bc28cb42d7ec5PharmaRadar360en2026-09-28T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-264d46ab86e050cdPharmaRadar360en2026-09-28T00:00:00.000ZProposed Data Collection Submitted for Public Comment and Recommendationshttps://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-7ad5b6a6771484a1PharmaRadar360en2026-09-28T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/privacy-act-of-1974-system-of-records-5b15b09af32ba802PharmaRadar360en2026-09-28T00:00:00.000ZPrivacy Act of 1974; System of Recordshttps://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-c50e681bff21b2f6PharmaRadar360en2026-09-28T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/inflammation-based-precision-medicine-for-depression-from-biomarkers-to-clinical-1b2c1f46fd916f51PharmaRadar360en2026-09-28T00:00:00.000ZInflammation-based Precision Medicine for Depression: From Biomarkers to Clinical Applicationhttps://www.pharmaradar360.com/article/prevalence-and-clinical-characteristics-of-myocardial-infarction-with-non-obstru-8f18da07504e278aPharmaRadar360en2026-09-28T00:00:00.000ZPrevalence and Clinical Characteristics of Myocardial Infarction With Non-obstructive Coronary Arteries Compared With Obstructive Myocardial Infarction: A Retrospective Tertiary-Centre Studyhttps://www.pharmaradar360.com/article/military-trial-of-emperor-bahadur-shah-zafar-an-assessment-of-its-legitimacy-har-8410153980f0f308PharmaRadar360en2026-09-28T00:00:00.000ZMilitary Trial of Emperor Bahadur Shah Zafar:An Assessment of its Legitimacy | Harf-o-sukhanhttps://www.pharmaradar360.com/article/the-incidence-of-alzheimer-s-disease-ad-is-rising-rapidly-yet-there-aren-t-defin-de75d7eba8000dfdPharmaRadar360en2026-09-28T00:00:00.000ZThe incidence of Alzheimer’s disease (AD) is rising rapidly, yet there aren’t definitive diagnostic methods or effective interventions that can treat AD. Growing evidence shows that music can influence the brain in a positive way, but music has often been treated as an undifferentiated whole, ratherhttps://www.pharmaradar360.com/article/peer-review-report-for-network-analysis-of-ct-derived-molecular-resistance-marke-8a2fd41021e7eda9PharmaRadar360en2026-09-28T00:00:00.000ZPeer Review Report For: Network Analysis of Ct-Derived Molecular Resistance Marker Pathways in Mycobacterium tuberculosis: Deciphering Drug-Resistance Architectures in Rural Eastern Cape, South Africa [version 1; peer review: 1 approved with reservations, 1 not approved]https://www.pharmaradar360.com/article/clinical-characteristics-and-outcomes-of-patients-with-chronic-digoxin-toxicity-f353518c0d4f8087PharmaRadar360en2026-09-28T00:00:00.000ZClinical Characteristics and Outcomes of Patients With Chronic Digoxin Toxicity Presenting to the Emergency Departmenthttps://www.pharmaradar360.com/article/clinical-efficacy-of-a-specific-synbiotic-formulation-in-restoring-fertility-in-2803237a7d5f92ccPharmaRadar360en2026-09-28T00:00:00.000ZClinical efficacy of a specific synbiotic formulation in restoring fertility in couples with persistent post-antibiotic dysbiosis: a pilot studyhttps://www.pharmaradar360.com/article/low-dose-i-vs-i-standard-dose-minocycline-in-bismuth-quadruple-therapy-for-first-7ab7e351f1b5408aPharmaRadar360en2026-09-28T00:00:00.000ZLow-dose <i>vs</i> standard-dose minocycline in bismuth quadruple therapy for first-line <i>Helicobacter pylori</i> eradication: A randomized controlled, noninferiority trialhttps://www.pharmaradar360.com/article/nanocrystals-in-cancer-treatment-b08f8dea59ec3b9cPharmaRadar360en2026-09-28T00:00:00.000ZNanocrystals in Cancer Treatmenthttps://www.pharmaradar360.com/article/713e753d98469f47PharmaRadar360en2026-09-28T00:00:00.000ZКеторолак при лечении эпизодов мигрени и головной боли напряжения в условиях реальной клинической практики: результаты исследования АУРАhttps://www.pharmaradar360.com/article/comparison-of-the-effects-of-high-intensity-laser-therapy-versus-low-level-laser-229dfa3e9933c7e2PharmaRadar360en2026-09-28T00:00:00.000ZComparison of the Effects of High-Intensity Laser Therapy versus Low-Level Laser Therapy on Pain, Function, and Range of Motion in Individuals with Sub-Acute Ankle Sprain: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/hemodialysis-associated-asymmetry-in-serum-zinc-concentrations-measured-by-icp-m-388351baee7ac7c2PharmaRadar360en2026-09-28T00:00:00.000ZHemodialysis-Associated Asymmetry in Serum Zinc Concentrations Measured by ICP-MS: A Paired Observational Clinical Studyhttps://www.pharmaradar360.com/article/immuno-oncology-in-pancreatic-ductal-adenocarcinoma-biological-rationale-clinica-d2af69b7e18765bcPharmaRadar360en2026-09-28T00:00:00.000ZImmuno-Oncology in Pancreatic Ductal Adenocarcinoma: Biological Rationale, Clinical Progress, and Future Directionshttps://www.pharmaradar360.com/article/long-term-drug-screening-identifies-parp-inhibitors-as-irinotecan-combination-pa-be742824351c0a78PharmaRadar360en2026-09-28T00:00:00.000ZLong-Term Drug Screening Identifies PARP Inhibitors as Irinotecan Combination Partners in BRCA1/2-Wild-Type Pancreatic Ductal Adenocarcinomahttps://www.pharmaradar360.com/article/physics-informed-and-explainable-artificial-intelligence-for-nanomaterial-based-a5f58a2643b2798bPharmaRadar360en2026-09-28T00:00:00.000ZPhysics-Informed and Explainable Artificial Intelligence for Nanomaterial-Based Biosensors: From Sensor Design and Signal Processing to Clinical Translationhttps://www.pharmaradar360.com/article/comparison-of-clinical-outcomes-between-mobile-and-fixed-bearing-unicompartmenta-6667180fba7f30d1PharmaRadar360en2026-09-28T00:00:00.000ZComparison of clinical outcomes between mobile- and fixed-bearing unicompartmental knee arthroplasty for medial compartment osteoarthritis: a retrospective studyhttps://www.pharmaradar360.com/article/efficacy-and-neural-mechanisms-of-transcutaneous-auricular-vagus-nerve-stimulati-72b60419550c43d9PharmaRadar360en2026-09-28T00:00:00.000ZEfficacy and neural mechanisms of transcutaneous auricular vagus nerve stimulation for chronic insomnia: a study protocol for a randomized controlled trialhttps://www.pharmaradar360.com/article/frequency-causes-and-duration-of-drug-shortages-in-south-korea-2018-2024-a-natio-e55a99c555cec6cbPharmaRadar360en2026-09-28T00:00:00.000ZFrequency, causes, and duration of drug shortages in South Korea, 2018–2024: a nationwide descriptive analysis of regulatory reporting data and temporal patterns across the COVID-19 pandemichttps://www.pharmaradar360.com/article/efficacy-mechanisms-and-influence-factors-of-small-molecule-targeted-therapy-in-44bdc0503d1fba30PharmaRadar360en2026-09-28T00:00:00.000ZEfficacy, mechanisms, and influence factors of small molecule targeted therapy in treating rheumatoid arthritis: a multi-dimensional clinical, immunological, and ultrasonographic studyhttps://www.pharmaradar360.com/article/reduced-serum-dickkopf-1-levels-as-a-potential-supportive-biomarker-for-the-deve-db77330620d95addPharmaRadar360en2026-09-28T00:00:00.000ZReduced serum Dickkopf-1 levels as a potential supportive biomarker for the development and severity of retinopathy of prematurity: a prospective observational clinical studyhttps://www.pharmaradar360.com/article/clinical-outcomes-and-prognostic-factors-of-ommaya-reservoir-based-intrathecal-c-dba36c44fd323c25PharmaRadar360en2026-09-28T00:00:00.000ZClinical outcomes and prognostic factors of Ommaya reservoir-based intrathecal chemotherapy in lung cancer leptomeningeal metastasis: a retrospective cohort studyhttps://www.pharmaradar360.com/article/a-logistic-paradigm-to-predict-molecular-glioblastoma-on-clinical-mri-d25870b0c44729ddPharmaRadar360en2026-09-28T00:00:00.000ZA logistic paradigm to predict molecular glioblastoma on clinical MRIhttps://www.pharmaradar360.com/article/global-perspectives-on-dietary-management-of-small-intestinal-bacterial-overgrow-71eb2092f4b9bc24PharmaRadar360en2026-09-28T00:00:00.000ZGlobal perspectives on dietary management of small intestinal bacterial overgrowth (SIBO): a systematic review of clinical guidelines, consensus statements and expert recommendationshttps://www.pharmaradar360.com/article/development-and-internal-temporal-validation-of-an-explainable-xgboost-model-for-f7790cbefaa8fb84PharmaRadar360en2026-09-28T00:00:00.000ZDevelopment and internal temporal validation of an explainable XGBoost model for predicting clinical pregnancy after frozen embryo transferhttps://www.pharmaradar360.com/article/antenatal-strategies-for-prevention-of-neonatal-hypoxic-ischemic-encephalopathy-295b666ebb90acf6PharmaRadar360en2026-09-28T00:00:00.000ZAntenatal strategies for prevention of neonatal hypoxic-ischemic encephalopathy: potential role of metforminhttps://www.pharmaradar360.com/article/prevalence-of-osteoporosis-and-its-correlation-with-clinical-variables-in-postme-e649c64cb7e17821PharmaRadar360en2026-09-28T00:00:00.000ZPrevalence of osteoporosis and its correlation with clinical variables in postmenopausal Iranian women with degenerative lumbar spinal stenosis: A cross-sectional pilot studyhttps://www.pharmaradar360.com/article/expanding-the-clinical-spectrum-of-terra-firma-forme-dermatosis-a-folliculo-papi-f35727dafb755dd7PharmaRadar360en2026-09-28T00:00:00.000ZExpanding the clinical spectrum of terra firma-forme dermatosis: A folliculo-papillomatous varianthttps://www.pharmaradar360.com/article/clinical-and-epidemiological-characteristics-of-patients-with-pemphigus-in-the-r-4043b596d94774ccPharmaRadar360en2026-09-28T00:00:00.000ZClinical and Epidemiological Characteristics of Patients with Pemphigus in the Russian Federation (Based on Patient Registry Data)https://www.pharmaradar360.com/article/effect-of-applying-educational-guidelines-of-arteriovenous-fistula-care-on-the-c-628da1afcbd2f3e4PharmaRadar360en2026-09-28T00:00:00.000ZEffect of Applying Educational Guidelines of Arteriovenous Fistula Care on the Clinical Outcome of Patients Undergoing Hemodialysishttps://www.pharmaradar360.com/article/follicular-unit-extraction-for-hair-restoration-in-stable-cicatricial-alopecia-s-f1b0742e7621233ePharmaRadar360en2026-09-28T00:00:00.000ZFollicular Unit Extraction for Hair Restoration in Stable Cicatricial Alopecia: Surgical Planning and Clinical Outcomes-A Case Serieshttps://www.pharmaradar360.com/article/when-conspiracies-are-true-exposure-to-documented-pharmaceutical-misconduct-unde-1e542ba722c340fcPharmaRadar360en2026-09-28T00:00:00.000ZWhen conspiracies are true: exposure to documented pharmaceutical misconduct undermines institutional trusthttps://www.pharmaradar360.com/article/cognitive-impairment-and-its-clinical-and-neuroimaging-correlates-in-fabry-disea-cb2b47933b51c4dbPharmaRadar360en2026-09-28T00:00:00.000ZCognitive Impairment and Its Clinical and Neuroimaging Correlates in Fabry Disease: A Single-Center Retrospective Cross-Sectional Studyhttps://www.pharmaradar360.com/article/orforglipron-versus-oral-semaglutide-in-type-2-diabetes-clinical-implications-of-d15d05dbbe9b021aPharmaRadar360en2026-09-28T00:00:00.000ZOrforglipron versus oral semaglutide in type 2 diabetes, clinical implications of the ACHIEVE-3 trialhttps://www.pharmaradar360.com/article/effects-of-virtual-reality-based-mindfulness-training-on-adhd-symptoms-and-emoti-2123cbb35924b834PharmaRadar360en2026-09-28T00:00:00.000ZEffects of Virtual Reality-Based Mindfulness Training on ADHD Symptoms and Emotion Regulation in Male Adolescents: A Randomized Clinical Trialhttps://www.pharmaradar360.com/article/a-trichoscopic-evaluation-of-hair-in-patients-of-male-pattern-hair-loss-on-oral-bc08e4f8dc4a9c96PharmaRadar360en2026-09-28T00:00:00.000ZA trichoscopic evaluation of hair in patients of male pattern hair loss on oral minoxidil: An open label single arm prospective observational studyhttps://www.pharmaradar360.com/article/microneedling-with-topical-5-5-fluorouracil-in-the-treatment-of-vitiligo-interve-e00d92879c051250PharmaRadar360en2026-09-28T00:00:00.000ZMicroneedling with topical 5% 5-fluorouracil in the treatment of vitiligo – interventional studyhttps://www.pharmaradar360.com/article/cutaneous-biofilms-microbial-communities-and-their-role-in-chronic-skin-infectio-a79d2b79d8e94658PharmaRadar360en2026-09-28T00:00:00.000ZCutaneous biofilms: Microbial communities and their role in chronic skin infectionshttps://www.pharmaradar360.com/article/clinicopathological-and-direct-immunofluorescence-correlation-in-the-diagnosis-o-34e5b49e44407113PharmaRadar360en2026-09-28T00:00:00.000ZClinicopathological and direct immunofluorescence correlation in the diagnosis of immunobullous disordershttps://www.pharmaradar360.com/article/comparative-study-on-the-effectiveness-of-coconut-oil-and-1-luliconazole-ointmen-42a8a0be160d69b5PharmaRadar360en2026-09-28T00:00:00.000ZComparative study on the effectiveness of coconut oil and 1% luliconazole ointment in reducing the DLQI and pruritic scale in patient with dermatophytosis in a tertiary care hospital in Chengalpattu district, Tamil Naduhttps://www.pharmaradar360.com/article/from-guidelines-to-real-world-practice-clinical-biochemical-and-genetic-insights-e2fa8909761e6719PharmaRadar360en2026-09-28T00:00:00.000ZFrom guidelines to real-world practice: clinical, biochemical, and genetic insights in a series of Moroccan patients with acid sphingomyelinase deficiencyhttps://www.pharmaradar360.com/article/feasibility-of-self-sampling-into-capillary-tubes-at-home-in-children-with-juven-7d79b3bb92bea184PharmaRadar360en2026-09-28T00:00:00.000ZFeasibility of self-sampling into capillary tubes at home in children with juvenile idiopathic arthritis: an observational studyhttps://www.pharmaradar360.com/article/microbiological-specification-criteria-of-non-sterile-pharmaceutical-drugs-and-t-7e310b175654f954PharmaRadar360en2026-09-28T00:00:00.000ZMicrobiological specification criteria of non-sterile pharmaceutical drugs and their formulations across pharmacopeias: A global perspectivehttps://www.pharmaradar360.com/article/artificial-intelligence-for-mri-based-identification-of-autism-spectrum-disorder-e8d5d9bef1bd07a4PharmaRadar360en2026-09-28T00:00:00.000ZArtificial Intelligence for MRI-Based Identification of Autism Spectrum Disorder: A Systematic Review of Methods, Performance, and Clinical Translationhttps://www.pharmaradar360.com/article/scalable-accountability-for-last-mile-child-health-service-delivery-a-cluster-ra-d3725773b0c51c9aPharmaRadar360en2026-09-28T00:00:00.000ZScalable Accountability for Last-Mile Child Health Service Delivery: A Cluster-Randomized Trial of Dimagi's Connect Child Health Campaign in Nigeriahttps://www.pharmaradar360.com/article/a-systems-biology-network-analysis-of-root-resorption-biomarkers-and-their-clini-32b79d375feaa0d8PharmaRadar360en2026-09-28T00:00:00.000ZA systems biology network analysis of root resorption biomarkers and their clinical relevance in orthodontics: a pilot studyhttps://www.pharmaradar360.com/article/troponin-biology-molecular-mechanisms-and-multidimensional-clinical-applications-5f2272f8daf94280PharmaRadar360en2026-09-28T00:00:00.000ZTroponin: biology, molecular mechanisms, and multidimensional clinical applicationshttps://www.pharmaradar360.com/article/assessment-of-clinical-and-surgical-outcomes-of-endoscopic-endonasal-transspheno-471c7eff2d5e608dPharmaRadar360en2026-09-28T00:00:00.000ZAssessment of clinical and surgical outcomes of endoscopic endonasal transsphenoidal resection of large pituitary adenomas: a prospective studyhttps://www.pharmaradar360.com/article/lymphocyte-subpopulation-characteristics-and-clinical-implications-in-treatment-5284517eb00e204dPharmaRadar360en2026-09-28T00:00:00.000ZLymphocyte subpopulation characteristics and clinical implications in treatment-naïve idiopathic inflammatory myopathieshttps://www.pharmaradar360.com/article/remodeling-metabolic-memory-persistent-epigenetic-injury-and-therapeutic-reversa-5c4b416d9155007dPharmaRadar360en2026-09-28T00:00:00.000ZRemodeling metabolic memory: persistent epigenetic injury and therapeutic reversal strategies in diabetic cardiomyopathyhttps://www.pharmaradar360.com/article/app-supported-powered-toothbrushing-during-non-surgical-periodontal-therapy-in-s-01d62e2a43458155PharmaRadar360en2026-09-28T00:00:00.000ZApp-supported powered toothbrushing during non-surgical periodontal therapy in stage III–IV periodontitis: a secondary analysis of a randomized controlled trialhttps://www.pharmaradar360.com/article/which-clinical-features-are-linked-with-severe-presentation-in-people-tested-for-6e8cd9316c5143aePharmaRadar360en2026-09-28T00:00:00.000ZWhich clinical features are linked with severe presentation in people tested for anti-GBM (glomerular basement membrane) antibodies?https://www.pharmaradar360.com/article/examining-site-level-and-structural-factors-influencing-the-recruitment-and-enga-26a71c1bb139c45ePharmaRadar360en2026-09-28T00:00:00.000ZExamining Site-Level and Structural Factors Influencing the Recruitment and Engagement of Participants of Color in Perinatal Substance Use Research: Insights From the Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs) Trialhttps://www.pharmaradar360.com/article/clinical-group-assignment-in-home-health-care-for-medicare-beneficiaries-with-ad-6a31b010e83c38f4PharmaRadar360en2026-09-28T00:00:00.000ZClinical Group Assignment in Home Health Care for Medicare Beneficiaries With ADRD: A 2019 Pre-PDGM Simulationhttps://www.pharmaradar360.com/article/letter-to-the-editor-regarding-methodological-considerations-for-evaluating-powe-27d591918e45a430PharmaRadar360en2026-09-28T00:00:00.000ZLetter to the editor regarding methodological considerations for evaluating power-assist devices in manual wheelchair usershttps://www.pharmaradar360.com/article/the-italian-version-of-the-lesbian-gay-bisexual-and-transgender-development-of-c-4d87368614e01b27PharmaRadar360en2026-09-28T00:00:00.000ZThe Italian Version of the Lesbian, Gay, Bisexual and Transgender Development of Clinical Skills Scale (LGBT-DOCSS): Validation Among Mental Health Professionalshttps://www.pharmaradar360.com/article/pembrolizumab-and-peptide-receptor-radionuclide-therapy-for-patients-with-metast-1825e74562a0e35bPharmaRadar360en2026-09-28T00:00:00.000ZPembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Metastatic Well-Differentiated Neuroendocrine Tumorshttps://www.pharmaradar360.com/article/quality-measures-as-clinical-defaults-reconsidering-sep-1-in-sepsis-resuscitatio-d99530ebc5216b61PharmaRadar360en2026-09-28T00:00:00.000ZQuality Measures as Clinical Defaults: Reconsidering SEP-1 in Sepsis Resuscitationhttps://www.pharmaradar360.com/article/proactive-heart-failure-screening-in-obesity-design-recruitment-and-baseline-cha-3968968376aff56dPharmaRadar360en2026-09-28T00:00:00.000ZProactive Heart Failure Screening in Obesity: Design, Recruitment and Baseline Characteristics of the SCORHFE Trialhttps://www.pharmaradar360.com/article/clinical-applicability-of-breath-measurements-for-detecting-disturbances-in-syst-06acb24d8d19452fPharmaRadar360en2026-09-28T00:00:00.000ZClinical applicability of breath measurements for detecting disturbances in systemic glucose metabolism: a systematised reviewhttps://www.pharmaradar360.com/article/monte-carlo-intercomparison-of-tg-43-dosimetric-parameters-for-clinical-mml-math-4f7b6d1a6a15717aPharmaRadar360en2026-09-28T00:00:00.000ZMonte Carlo intercomparison of TG-43 dosimetric parameters for clinical <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:mrow> <mml:msup> <mml:mrow/> <mml:mrow> <mml:mn>192</mml:mn> </mml:mrow> </mml:msup> </mml:mrow> </mml:math> Ir and <mml:math xmlns:mml="http://www.w3.org/1998/Math/https://www.pharmaradar360.com/article/toward-a-meta-framework-for-addressing-antisemitism-in-psychotherapy-ecological-7178384423ebecb4PharmaRadar360en2026-09-28T00:00:00.000ZToward a meta-framework for addressing antisemitism in psychotherapy: Ecological Systems Theory in clinical practicehttps://www.pharmaradar360.com/article/molecular-mechanisms-of-resistance-to-kras-sup-g12c-sup-inhibitors-in-nsclc-from-de4fbbf7eabc1d21PharmaRadar360en2026-09-28T00:00:00.000ZMolecular Mechanisms of Resistance to KRAS ^G12C Inhibitors in NSCLC- From Genomic Evolution to TME Adaptationhttps://www.pharmaradar360.com/article/spotlights-on-cervical-cancer-progression-diagnosis-and-clinical-manifestations-57ee506f3d085699PharmaRadar360en2026-09-28T00:00:00.000ZSpotlights on Cervical Cancer: Progression, Diagnosis and Clinical Manifestations, Epidemiology, Treatment Approaches, Role of Artificial Intelligence and Future Directionshttps://www.pharmaradar360.com/article/3d-printed-plcl-scaffolds-for-breast-reconstructive-tissue-engineering-a-pre-cli-f23640d61fd17384PharmaRadar360en2026-09-28T00:00:00.000Z3D-printed PLCL scaffolds for breast reconstructive tissue engineering: a pre-clinical study in a rabbit modelhttps://www.pharmaradar360.com/article/response-adapted-postoperative-therapy-following-neoadjuvant-chemoimmunotherapy-4d82ea2ca9c97cecPharmaRadar360en2026-09-28T00:00:00.000ZResponse-Adapted Postoperative Therapy Following Neoadjuvant Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: a phase II trialhttps://www.pharmaradar360.com/article/supplemental-material-for-effects-of-a-brief-self-administered-somatosensory-int-412e3b1db6aaa988PharmaRadar360en2026-09-28T00:00:00.000ZSupplemental Material for Effects of a Brief Self-Administered Somatosensory Intervention on Affective Regulation Under Occupational Stress: A Randomized Controlled Trial Among Nurseshttps://www.pharmaradar360.com/article/deg2mol-conditional-latent-flow-matching-for-transcriptome-guided-i-de-novo-i-dr-0f7bea41aada6c0ePharmaRadar360en2026-09-28T00:00:00.000ZDEG2MOL: Conditional Latent Flow Matching for Transcriptome-Guided <i>de novo</i> Drug Designhttps://www.pharmaradar360.com/article/unusually-rotated-total-talar-fracture-dislocation-a-case-report-and-review-of-t-c8979b8d65c3bd8aPharmaRadar360en2026-09-28T00:00:00.000ZUnusually Rotated Total Talar Fracture-Dislocation: A Case Report and Review of the Literaturehttps://www.pharmaradar360.com/article/anthropometric-indices-metabolic-derangements-and-modifiable-lifestyle-factors-a-5a9aa3505de6a76cPharmaRadar360en2026-09-28T00:00:00.000ZAnthropometric Indices, Metabolic Derangements, and Modifiable Lifestyle Factors as Independent Determinants of Male Infertilityhttps://www.pharmaradar360.com/article/overall-survival-of-patients-with-salivary-gland-carcinoma-in-saudi-arabia-using-545d694a056123e3PharmaRadar360en2026-09-28T00:00:00.000ZOverall survival of patients with salivary gland carcinoma in saudi arabia using latent clinical profiles in a retrospective cohort studyhttps://www.pharmaradar360.com/article/avoidance-distance-in-dairy-cattle-as-a-behavioural-indicator-of-fear-responses-f68e52fa79520722PharmaRadar360en2026-09-28T00:00:00.000ZAvoidance distance in dairy cattle as a behavioural indicator of fear responses: the confounding role of clinical health status in two Algerian dairy farmshttps://www.pharmaradar360.com/article/alk-ati-in-solid-tumours-biological-evidence-diagnostic-challenges-and-clinical-08e5fab24265ec3cPharmaRadar360en2026-09-28T00:00:00.000ZALK ATI in solid tumours: biological evidence, diagnostic challenges, and clinical relevance. a narrative reviewhttps://www.pharmaradar360.com/article/circulating-tumour-dna-and-its-clinical-relevance-in-predicting-progression-free-fd15e6b814bb6160PharmaRadar360en2026-09-28T00:00:00.000ZCirculating tumour DNA and its clinical relevance in predicting progression-free survival and overall survival in patients with advanced breast cancer: a systematic review and meta-analysishttps://www.pharmaradar360.com/article/acute-effects-of-binge-drinking-following-aerobic-exercise-on-autonomic-and-hemo-cea6315ab89bddcePharmaRadar360en2026-09-28T00:00:00.000ZAcute effects of binge drinking following aerobic exercise on autonomic and hemodynamic recovery in young men: a randomized crossover trialhttps://www.pharmaradar360.com/article/how-laser-etching-affects-the-clinical-performance-of-a-no-wait-universal-adhesi-bf675b7ceeddc901PharmaRadar360en2026-09-28T00:00:00.000ZHow laser etching affects the clinical performance of a “no-wait” universal adhesive: 36-month resultshttps://www.pharmaradar360.com/article/correction-remote-smartphone-based-spoken-language-screening-predicts-clinical-m-785362258d5bd464PharmaRadar360en2026-09-28T00:00:00.000ZCorrection: Remote smartphone-based spoken language screening predicts clinical markers in Huntington’s diseasehttps://www.pharmaradar360.com/article/effects-of-natriuresis-guided-diuretic-therapy-in-men-and-women-with-acute-heart-988b285ab52886d3PharmaRadar360en2026-09-28T00:00:00.000ZEffects of natriuresis-guided diuretic therapy in men and women with acute heart failure: insights from PUSH-AHFhttps://www.pharmaradar360.com/article/clinical-outcomes-of-meniscal-repair-using-bone-marrow-aspirate-derived-fibrin-c-907f6f080f560401PharmaRadar360en2026-09-28T00:00:00.000ZClinical outcomes of meniscal repair using bone marrow aspirate-derived fibrin clot: A comparison of tears with and without meniscal cystshttps://www.pharmaradar360.com/article/ctcf-fxn-regulatory-axis-plays-critical-roles-in-clinical-assessments-and-diseas-e0f7d507d0eba4a2PharmaRadar360en2026-09-28T00:00:00.000ZCTCF-FXN regulatory axis plays critical roles in clinical assessments and disease progression of primary open-angle glaucomahttps://www.pharmaradar360.com/article/clinical-considerations-on-hpv-knowledge-screening-and-vaccination-in-brazilian-db81786e0245a1e8PharmaRadar360en2026-09-28T00:00:00.000ZClinical Considerations on HPV Knowledge, Screening, and Vaccination in Brazilian Primary Care: Letter to the Editorhttps://www.pharmaradar360.com/article/mitochondrial-metabolic-reprogramming-in-glioma-mechanisms-of-tumorigenesis-and-81ce9c7cc6186131PharmaRadar360en2026-09-28T00:00:00.000ZMitochondrial Metabolic Reprogramming in Glioma: Mechanisms of Tumorigenesis and Implications for Clinical Therapyhttps://www.pharmaradar360.com/article/successful-empirical-treatment-of-a-severe-corneal-abscess-after-delayed-consult-b5042aeab2865dd2PharmaRadar360en2026-09-28T00:00:00.000ZSuccessful Empirical Treatment of a Severe Corneal Abscess After Delayed Consultation in a Low‐Resource Setting: A Case Reporthttps://www.pharmaradar360.com/article/pyloric-pseudonecrosis-caused-by-biliary-peritonitis-a-rare-intraoperative-pitfa-36095fdd76be4059PharmaRadar360en2026-09-28T00:00:00.000ZPyloric Pseudonecrosis Caused by Biliary Peritonitis: A Rare Intraoperative Pitfallhttps://www.pharmaradar360.com/article/dorsal-pancreatic-agenesis-associated-with-new-onset-diabetes-mellitus-and-acute-3679036fc828411aPharmaRadar360en2026-09-28T00:00:00.000ZDorsal Pancreatic Agenesis Associated With New‐Onset Diabetes Mellitus and Acute Pancreatitis in an 18‐Year‐Old Man: A Case Reporthttps://www.pharmaradar360.com/article/nct07844915-artificial-intelligence-enhanced-remote-monitoring-in-interstitial-l-f8c6795ed3607a53PharmaRadar360en2026-09-28T00:00:00.000ZNCT07844915: Artificial Intelligence Enhanced Remote Monitoring in Interstitial Lung Diseasehttps://www.pharmaradar360.com/article/nct07844850-biomarkers-as-prognostic-factors-of-silent-cerebral-infarctions-in-p-3f48d5cef9d31d76PharmaRadar360en2026-09-28T00:00:00.000ZNCT07844850: Biomarkers as Prognostic Factors of Silent, Cerebral Infarctions in Patients Undergoing High-thromboembolic-risk Transcatheter Interventionshttps://www.pharmaradar360.com/article/nct07844707-exercise-and-health-education-for-musculoskeletal-health-in-industri-3134f9849459de40PharmaRadar360en2026-09-28T00:00:00.000ZNCT07844707: Exercise and Health Education for Musculoskeletal Health in Industrial Workershttps://www.pharmaradar360.com/article/nct07844538-jlu-nutr-fi-registry-a-prospective-registry-of-feeding-intolerance-i-2074efd5e61ba54fPharmaRadar360en2026-09-28T00:00:00.000ZNCT07844538: JLU_Nutr_FI Registry: A Prospective Registry of Feeding Intolerance in Critically Ill Patientshttps://www.pharmaradar360.com/article/nct07843771-efficacy-and-safety-of-selected-traditional-chinese-medicine-elbow-m-063cfbca3bf2fceePharmaRadar360en2026-09-28T00:00:00.000ZNCT07843771: Efficacy and Safety of Selected Traditional Chinese Medicine Elbow Manipulation Versus Mill's Manipulation as Control for Lateral Epicondylitis